Sanofi Consumer Healthcare India Q2 Revenue Reaches ₹235.7 Crore

MUMBAI — Sanofi Consumer Healthcare India Limited announced its unaudited financial results for the second quarter ended June 30, 2026, reporting a 7% year-on-year increase in revenue from operations to ₹2,357 million (₹235.7 crore). The Mumbai-based consumer health firm filed its quarterly earnings disclosures with the BSE Limited and the National Stock Exchange of India Limited on Tuesday following a board meeting.

The company posted a consolidated net profit of ₹688 million (₹68.8 crore) for the April–June quarter, up from ₹607 million recorded in the corresponding period of the previous year. The quarterly financial results reflect sustained demand in the domestic market following the successful relaunch and stabilization of key consumer healthcare brands.

Financial Highlights and Domestic Performance

During the second quarter of 2026, domestic sales for Sanofi Consumer Healthcare India grew 12% year-on-year, supported by full product availability across retail and distribution channels. Profit Before Tax (PBT) for the quarter rose 16% year-on-year to ₹919 million (₹91.9 crore) compared to ₹789 million in Q2 2025.

For the first half of the year (January to June 2026), total revenue from operations reached ₹4,649 million (₹464.9 crore), representing an 18% increase compared to ₹3,935 million in the first half of 2025. Profit Before Tax for H1 2026 climbed 25% year-on-year to ₹1,826 million.

Market Dynamics and Operational Context

The company's performance was shaped by contrasting trends across domestic and international segments:

• Domestic Growth: Domestic revenue expanded by 12% during the quarter, aided by product relaunches including Allegra Suspension, Combiflam Suspension, and Depura Kids. These products had been voluntarily recalled in 2024 as a precautionary measure and re-introduced to the market in mid-to-late 2025.

• Export Revenues: Export sales registered a 9% decline during Q2 2026, primarily due to a high baseline in the corresponding quarter of 2025. However, on a half-yearly basis, export sales grew 27% year-on-year.

• Corporate Structure: Sanofi Consumer Healthcare India Limited emerged as an independent legal entity following its demerger from Sanofi India Limited on June 1, 2024, focusing strictly on over-the-counter (OTC) and self-care categories.

Official Sources Section

Financial data, business metrics, and executive comments in this article are derived from official regulatory filings submitted by Sanofi Consumer Healthcare India Limited to the BSE Limited (Scrip Code: 544250) and National Stock Exchange of India Limited (Symbol: SANOFICONR) on July 28, 2026.

Executive Commentary

Commenting on the quarterly results, Himanshu Bakshi, Managing Director of Sanofi Consumer Healthcare India Limited, stated:

"Our performance this quarter reflects the disciplined execution on all fronts. Our targeted investments behind our brands and go-to-market capabilities are translating into profitable growth and market share gains in most of our brands, reinforcing our confidence in the strength of our strategy."

Why It Matters

• For Consumers: Stable distribution and product availability ensure uninterrupted access to allergy, pain management, and vitamin supplements across pharmacy networks.

• For Investors: A 16% jump in quarterly PBT and healthy cash reserves of ₹4,902 million highlight operational efficiency following the corporate demerger.

• For the Healthcare Sector: Demonstrates recovery in consumer self-care categories following regulatory supply chain realignments.

Key Facts at a Glance

• Quarterly Revenue: Revenue from operations reached ₹2,357 million (₹235.7 crore) in Q2 2026.

• Net Profit: Quarterly profit after tax rose to ₹688 million (₹68.8 crore).

• Domestic Sales: Expanded 12% year-on-year driven by key brand momentum.

• Half-Year Revenue: H1 2026 operational revenue grew 18% to ₹4,649 million.

• Market Listings: Traded on the BSE under code 544250 and NSE under symbol SANOFICONR.

Frequently Asked Questions

What was Sanofi Consumer Healthcare India's revenue for Q2 2026?

Sanofi Consumer Healthcare India Limited reported revenue from operations of ₹2,357 million (₹235.7 crore) for the quarter ended June 30, 2026, representing a 7% year-on-year growth.

How much net profit did the company make in the second quarter?

The company generated a net profit of ₹688 million (₹68.8 crore) for Q2 2026, up from ₹607 million recorded in Q2 2025.

What driven the growth in domestic sales?